Clinical application and evaluation of health economics for non-invasive prenatal testing of fetuses in Tianjin.
10.3760/cma.j.cn511374-20210210-00127
- Author:
Ruiyu MA
1
;
Xiaozhou LI
;
Song XU
;
Yunfang SHI
;
Duan JU
;
Yan LI
;
Fanrong MENG
;
Xiuyan WANG
;
Xinxin DU
;
Naiwei XU
;
Ying ZHANG
Author Information
1. Department of Gynecology and Obstetrics, General Hospital of Tianjin Medical University, Tianjin 300052, China. tjzyyzy@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Pregnancy;
Female;
Humans;
Trisomy/genetics*;
Retrospective Studies;
Prenatal Diagnosis/methods*;
Down Syndrome/genetics*;
Aneuploidy;
Chromosome Aberrations;
Trisomy 18 Syndrome/genetics*;
Sex Chromosome Aberrations;
Fetus
- From:
Chinese Journal of Medical Genetics
2023;40(2):135-142
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the clinical efficacy and health economic value of non-invasive prenatal testing (NIPT) for the prenatal screening of common fetal chromosomal aneuploidies.
METHODS:10 612 pregnant women from October 2017 to December 2019 presented at the antenatal screening clinic of the General Hospital of Tianjin Medical University were selected as the study subjects. Results of NIPT and invasive prenatal diagnosis and follow-up outcome for the 10 612 pregnant women were retrospectively analyzed and compared. Meanwhile, NIPT data for two periods were analyzed for assessing the health economic value of NIPT as the second- or first-tier screening strategy for the prenatal diagnosis of fetal trisomies 21, 18 and 13.
RESULTS:The NIPT was successful in 10 528 (99.72%) subjects, with the sensitivity for fetal trisomies 21, 18 and 13 being 100%, 92.86% and 100%, and the positive predictive value (PPV) being 89.74%, 61.90% and 44.44%, respectively. The PPV of NIPT for sex chromosome aneuploidies was 34.21%. Except for one false negative case of trisomy 18, the negative predictive value for trisomy 21, trisomy 13 and other chromosomal abnormalities were 100%. For pregnant women with high risk by serological screening, advanced maternal age or abnormal ultrasound soft markers, NIPT has yielded a significantly increased high risk ratio. There was no statistical difference in the PPV of NIPT among pregnant women from each subgroup. NIPT would have higher health economic value as a second-tier screening until 2019, while compared to 2015 ~ 2017, its incremental cost-effectiveness ratio as a first-tier screening had declined clearly.
CONCLUSION:The screening efficacy of NIPT for trisomies 21, 18 and 13 for a mixed population is significantly better than conventional serological screening, but it is relatively low for sex chromosomal abnormalities. NIPT can also be recommended for populations with relatively high risks along with detailed pre- and post-test genetic counselling. From the perspective of health economics, except for open neural tube defects, it is possible for NIPT to replace the conventional serological screening in the future as its cost continues to decrease.
